Form PREM14A - Preliminary proxy statements relating to merger or acquisition:
SEC Accession No. 0001140361-23-049203
Filing Date
2023-10-23
Accepted
2023-10-23 17:31:11
Documents
4
Period of Report
2023-10-23

Document Format Files

Seq Description Document Type Size
1 PREM14A edge20012673x1_prem14a.htm PREM14A 2756311
2 FILING FEES TABLE edge20012673x1_ex107.htm EX-FILING FEES 25175
3 edge20012673x1_pc-01x1.jpg GRAPHIC 675368
4 edge20012673x1_pc-02.jpg GRAPHIC 493259
  Complete submission text file 0001140361-23-049203.txt   4391274
Mailing Address 3545 CRAY COURT SAN DIEGO CA 92121
Business Address 3545 CRAY COURT SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

EIN.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PREM14A | Act: 34 | File No.: 001-35921 | Film No.: 231340681
SIC: 2834 Pharmaceutical Preparations